The data provide a rationale to explore repurposing of Tocilizumab and other clinically approved monoclonal antibodies interfering with binding of IL-6 to its cognate receptor subunit to test their clinical efficacy for the treatment for IBC patients with clinical evidence of IL-6-dependent STAT3 activation in their lesions. The gene discussed is IL6; the disease is inflammatory breast carcinoma.